key: cord-0767987-koim4e9q
authors: Drummond, David; Thumerelle, Caroline; Roux, Antoine; Mordacq, Clémence; Frange, Pierre; Leruez‐Ville, Marianne; Gibault, Laure; Berteloot, Laureline; Roy, Charlotte; Pontailler, Margaux; Lopez, Vanessa; Oualha, Mehdi; Grimaud, Marion; de Saint Blanquat, Laure; Parquin, François; Sermet‐Gaudelus, Isabelle
title: Severe COVID‐19 evolving towards organizing pneumonia in a pediatric lung transplant recipient
date: 2021-11-02
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.25744
sha: e980431caac33431bddad44e170a341a24040ffc
doc_id: 767987
cord_uid: koim4e9q

nan

To the Editor, Lung transplantation (LT) and rituximab represent two risk factors for severe COVID-19 in adults. 1 Conversely, pediatric solid organ recipients and children receiving rituximab did not appear to be at increased risk for severe COVID-19, which led some authors to suggest that children on immunosuppressive therapy should not be more strictly isolated than children who are not. 2 

A 12-year-old girl developed a severe form of COVID-19 10 months after a bilateral LT indicated end-stage respiratory failure due to cystic fibrosis. The transplant course was marked by an Epstein-Barr virus + polymorphic posttransplant lymphoproliferative disorder treated with rituximab (four weekly infusions of 375 mg/m 2 ) between months 9 and 10 post-LT. Tacrolimus, mycophenolate mofetil, and prednisone composed the maintenance immunosuppressive regimen.

Between the third and fourth rituximab infusion, the patient developed a cough, fever, and respiratory distress requiring a maximal oxygen flow of 2.5 L/min due to severe acute respiratory syn- Similarly, rituximab was initially not associated with worse outcomes in children infected by SARS-Cov2. In a study involving 113 children with kidney diseases taking immunosuppressive therapies, Marlais et al. 2 concluded that because most children had mild diseases with SARS-Cov2 infection, they should not be more strictly isolated than other children.

However, looking closely at the data, of the 12 children who received anti-CD20 therapy, 3 children received supplemental oxygen, and 1 required noninvasive ventilation. 2 Thus, we speculate that the high level of immunosuppression including combined B-and T-cell deficiency due to the association of rituximab, tacrolimus, mycophenolate mofetil, and prednisone prevented the elicitation of a specific SARS-Cov2 immune response in our patient.

Despite the early and repeated use of CCP, our patient developed organizing pneumonia. Organizing pneumonia is a nonspecific pulmonary response pattern associated with a variety of clinical contexts including connective tissue diseases, drug reactions, and viral infection. Classically, peribronchovascular/peripheral ground glass opacities or consolidations which can be migratory are observed on chest CT scans, and a prolonged course of corticosteroids allow remission in most cases. Organized pneumonia had been reported in adults with COVID-19 but never before in a pediatric patient. 5 The increase in prednisone to 2 mg/kg/day improved the pulmonary status of our patient, but did not prevent the emergence of sequela under the form of areas of pulmonary fibrosis.

Pierre Frange is a consultant for and has received travel support from

investigation (equal); writing -original draft (lead)

Pierre Frange: investigation (equal); writing -review and editing (equal). Marianne Leruez: investigation (equal); writing -review and editing (equal)

Charlotte Roy: investigation (equal); writing -review and editing (equal)

Mehdi Oualha: investigation (equal); writing -review and editing (equal). Marion Grimaud: investigation (equal); writing -review and editing (equal)

writing -review and editing (equal)

COVID-19 in lung transplant recipients

COVID-19 in children treated with immunosuppressive medication for kidney diseases

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

The pediatric solid organ transplant experience with COVID-19: an initial multi-center, multiorgan case series

Radiology-pathology correlation demonstrating organizing pneumonia in a patient who recovered from COVID-19